InflaRx NV Net Income Over Time
| IFRX Stock | USD 0.85 0.01 0.78% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out InflaRx NV Performance and InflaRx NV Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InflaRx NV. Market participants price InflaRx higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive InflaRx NV assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.73) | Revenue Per Share | Quarterly Revenue Growth (0.81) | Return On Assets | Return On Equity |
Understanding InflaRx NV requires distinguishing between market price and book value, where the latter reflects InflaRx's accounting equity. The concept of intrinsic value - what InflaRx NV's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push InflaRx NV's price substantially above or below its fundamental value.
Please note, there is a significant difference between InflaRx NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if InflaRx NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, InflaRx NV's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare InflaRx NV and related stocks such as Shattuck Labs, Connect Biopharma, and ImageneBio Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STTK | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (24 M) | (35.4 M) | (45 M) | (100.6 M) | (87.3 M) | (75.4 M) | (67.9 M) | (71.3 M) |
| CNTB | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (120.3 M) | (205.2 M) | (116.4 M) | (59.5 M) | (15.6 M) | (18 M) | (18.9 M) |
| IMA | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (40.9 M) | (16.8 M) | (44.3 M) | (34.1 M) | (68.8 M) | (68.2 M) | (36.6 M) | (32.9 M) | (34.6 M) |
| KLRS | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (23.8 M) | (69.8 M) | (172 M) | (15.5 M) | (14.7 M) | (58.8 M) | (52.9 M) | (55.5 M) |
| ARTV | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (71.8 M) | (58.4 M) | (27.7 M) | (58.5 M) | (52.6 M) | (55.3 M) |
| STRO | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | (19.7 M) | (35.3 M) | (55.7 M) | (32.1 M) | (105.5 M) | (119.2 M) | (106.8 M) | (227.5 M) | (204.7 M) | (194.5 M) |
| QNCX | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.5 M) | (37 M) | (76.8 M) | (89.9 M) | (51.7 M) | (31.4 M) | (56.8 M) | (51.1 M) | (53.7 M) |
| MGX | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (43.6 M) | (68.3 M) | (78.1 M) | (78.1 M) | (70.3 M) | (73.8 M) |
| CNTX | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (24.6 M) | (7.5 M) | (7.5 M) | 6.6 M | (10.5 M) | (14.8 M) | (24 M) | (26.7 M) | (30.7 M) | (32.3 M) |
| ATYR | (17.6 M) | (17.6 M) | (17.6 M) | (20 M) | (24.4 M) | (48 M) | (57.9 M) | (48.2 M) | (34.5 M) | (23.6 M) | (16.2 M) | (33.8 M) | (45.3 M) | (50.4 M) | (64 M) | (57.6 M) | (60.5 M) |
InflaRx NV and related stocks such as Shattuck Labs, Connect Biopharma, and ImageneBio Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in InflaRx NV financial statement analysis. It represents the amount of money remaining after all of InflaRx NV operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| InflaRx NV | IFRX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Winzerlaer Str 2, |
| Exchange | NASDAQ Exchange |
USD 0.8533
Additional Tools for InflaRx Stock Analysis
When running InflaRx NV's price analysis, check to measure InflaRx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InflaRx NV is operating at the current time. Most of InflaRx NV's value examination focuses on studying past and present price action to predict the probability of InflaRx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InflaRx NV's price. Additionally, you may evaluate how the addition of InflaRx NV to your portfolios can decrease your overall portfolio volatility.